Zobrazeno 1 - 10
of 18
pro vyhledávání: '"and the ODYSSEY Trial Team"'
Autor:
Rebecca M. Turner, Anna Turkova, Cecilia L. Moore, Alasdair Bamford, Moherndran Archary, Linda N. Barlow-Mosha, Mark F. Cotton, Tim R. Cressey, Elizabeth Kaudha, Abbas Lugemwa, Hermione Lyall, Hilda A. Mujuru, Veronica Mulenga, Victor Musiime, Pablo Rojo, Gareth Tudor-Williams, Steven B. Welch, Diana M. Gibb, Deborah Ford, Ian R. White, and the ODYSSEY Trial Team
Publikováno v:
BMC Medical Research Methodology, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Clinical trial investigators may need to evaluate treatment effects in a specific subgroup (or subgroups) of participants in addition to reporting results of the entire study population. Such subgroups lack power to detect a treat
Externí odkaz:
https://doaj.org/article/4630e04e33764bccb00fb99114b172c4
Autor:
Linda Namutebi Barlow‐Mosha, Grace Miriam Ahimbisibwe, Elizabeth Chappell, Pauline Mary Amuge, Annet Nanduudu, Elizabeth Kaudha, Timothy Amukele, David Balamusani, Bosco Kafufu, Audrey Nimwesiga, Hajira Kataike, Rosemary Namwanje, Gladys Kasangaki, Alice Mulindwa, Gerald Agaba Muzorah, Dickson Bbuye, Victor Musiime, Emmanuel Mujyambere, Mark Ssenyonga, Disan Mulima, Raymonds Crespo Kyambadde, Josephine Namusanje, Richard Isabirye, Mariam Nabalamba, Barbara Musoke Nakirya, Cissy Kityo, Adeodata R. Kekitiinwa, Carlo Giaquinto, Andrew Copp, Diana M. Gibb, Deborah Ford, Philippa Musoke, Anna Turkova, the ODYSSEY trial team
Publikováno v:
Journal of the International AIDS Society, Vol 26, Iss 9, Pp n/a-n/a (2023)
Abstract Introduction Dolutegravir‐based antiretroviral therapy (ART) is the preferred antiretroviral treatment for children and adolescents living with HIV. A large surveillance study in Botswana previously raised concerns about an association bet
Externí odkaz:
https://doaj.org/article/4eb8105cdfec4abaae8c29869b2424a5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Anna Turkova, Ellen White, Adeodata R. Kekitiinwa, Vivian Mumbiro, Elizabeth Kaudha, Afaaf Liberty, Grace Miriam Ahimbisibwe, Tumelo Moloantoa, Ussanee Srirompotong, Nozibusiso Rejoice Mosia, Thanyawee Puthanakit, Robin Kobbe, Clàudia Fortuny, Hajira Kataike, Dickson Bbuye, Sathaporn Na-Rajsima, Alexandra Coelho, Abbas Lugemwa, Mutsa F. Bwakura-Dangarembizi, Nigel Klein, Hilda Mujuru, Cissy Kityo, Mark F. Cotton, Rashida Abbas Ferrand, Carlo Giaquinto, Pablo Rojo Conejo, Avy Violari, Diana M. Gibb, Deborah Ford, ODYSSEY Trial Team
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e19ccbaadfff4ab13b06cbaacbf9beb
https://doi.org/10.2139/ssrn.4380060
https://doi.org/10.2139/ssrn.4380060
Autor:
Turner, Rebecca M, Turkova, Anna, Moore, Cecilia L, Bamford, Alasdair, Archary, Moherndran, Barlow-Mosha, Linda N, Cotton, Mark F, Cressey, Tim R, Kaudha, Elizabeth, Lugemwa, Abbas, Lyall, Hermione, Mujuru, Hilda A, Mulenga, Veronica, Musiime, Victor, Rojo, Pablo, Tudor-Williams, Gareth, Welch, Steven B, Gibb, Diana M, Ford, Deborah, White, Ian R, the ODYSSEY Trial Team, ODYSSEY Trial Team
BACKGROUND: Clinical trial investigators may need to evaluate treatment effects in a specific subgroup (or subgroups) of participants in addition to reporting results of the entire study population. Such subgroups lack power to detect a treatment eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::dd57d220f3b7d521c03e90801823f3c7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Waalewijn, Hylke, Chan, Man K, Bollen, Pauline DJ, Mujuru, Hilda A, Makumbi, Shafic, Kekitiinwa, Adeodata R, Kaudha, Elizabeth, Sarfati, Tatiana, Musoro, Godfrey, Nanduudu, Annet, Lugemwa, Abbas, Amuge, Pauline, Moore, Cecilia L, Rojo, Pablo, Giaquinto, Carlo, Colbers, Angela, Gibb, Diana M, Ford, Deborah, Turkova, Anna, Burger, David M, ODYSSEY Trial Team
BACKGROUND: Dolutegravir-based antiretroviral therapy is a preferred first-line treatment for adults and children living with HIV; however, very little pharmacokinetic data for dolutegravir use are available in young children. We therefore aimed to e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::86f4247b2d9185afcfe34294e9c39cbe
https://researchonline.lshtm.ac.uk/id/eprint/4665977/1/1-s2.0-S2352301821002927-main.pdf
https://researchonline.lshtm.ac.uk/id/eprint/4665977/1/1-s2.0-S2352301821002927-main.pdf
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Annet Nanduudu, James Hakim, Deborah Ford, Angela Colbers, Odyssey trial team, Abbas Lugemwa, Carlo Giaquinto, Adeodata Kekitiinwa, David M. Burger, Diana M. Gibb, Pauline D.J. Bollen, Pablo Rojo, Cecilia L. Moore, Godfrey Musoro, Pauline Amuge, Hilda Mujuru, Anna Turkova, Anna Parker, Elisabeth Kaudha, Shafic Makumbi
Publikováno v:
The Lancet HIV, 7, 8, pp. E533-E544
The Lancet HIV, 7, E533-E544
The Lancet. HIV
The Lancet HIV, 7, E533-E544
The Lancet. HIV
Summary Background Paediatric dolutegravir doses approved by stringent regulatory authorities (SRAs) for children weighing 20 kg to less than 40 kg until recently required 25 mg and 10 mg film-coated tablets. These tablets are not readily available i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95bde7a36ececd1b83bf7f35babed020
https://hdl.handle.net/2066/221577
https://hdl.handle.net/2066/221577